Can specially grown immune cells from donors beat viruses that won't go away?

NCT ID NCT06926894

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether immune cells called R-MVST cells, grown quickly from a healthy donor, can safely fight off stubborn viral infections (EBV, CMV, adenovirus, or BK virus) in children and young adults with weakened immune systems. Participants have not responded to standard treatments. The study will closely monitor for side effects, including graft-versus-host disease, and check whether the infusion lowers viral levels and helps the body recover its own antiviral defenses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rapidly generated virus specific T (R-MVST) cells from a healthy donor
What this could lead to
If it works, this approach could offer a new way to treat severe viral infections in patients with weak immune systems who have not responded to standard treatments.
What could go wrong
This is a very early phase 1 trial with only 18 participants, so safety and feasibility are the main focus. There is a risk of graft-versus-host disease or other serious side effects from the donor cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Medical Center / New-York Presbyterian

    RECRUITING

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.